✦ LIBER ✦

Rituximab in three children with relapsed/refractory B-cell acute lymphoblastic leukaemia/Burkitt non-Hodgkin's lymphoma

✍ Scribed by Maaike J. De Vries; Anjo J. P. Veerman; Christian M. Zwaan

Book ID: 108672614
Publisher: John Wiley and Sons
Year: 2004
Tongue: English
Weight: 50 KB
Volume: 125
Category: Article
ISSN: 0007-1048
DOI: 10.1111/j.1365-2141.2004.04925.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Use of rituximab in three children with

Use of rituximab in three children with relapsed/refractory Burkitt lymphoma

✍ Sinan Akbayram; Murat Doğan; Cihangir Akgün; Fatih Erbey; Hüseyin Çaksen; Ahmet 📂 Article 📅 2010 🏛 Springer-Verlag 🌐 English ⚖ 90 KB

Feasibility and pharmacokinetic study of

Feasibility and pharmacokinetic study of bendamustine hydrochloride in combination with rituximab in relapsed or refractory aggressive B cell non-Hodgkin’s lymphoma

✍ Michinori Ogura; Kiyoshi Ando; Masafumi Taniwaki; Takashi Watanabe; Toshiki Uchi 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 232 KB

Improved cure rate in children with B-ce

Improved cure rate in children with B-cell acute lymphoblastic leukaemia (B-ALL) and stage IV B-cell non-Hodgkin's lymphoma (B-NHL) - results of the UKCCSG 9003 protocol

✍ Atra, A; Gerrard, M; Hobson, R; Imeson, JD; Ashley, S; Pinkerton, CR 📂 Article 📅 1998 🏛 Nature Publishing Group 🌐 English ⚖ 819 KB

Phase II study of a salvage regimen usin

Phase II study of a salvage regimen using cyclophosphamide, high-dose cytarabine, dexamethasone, etoposide, and rituximab in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma

✍ Yasuhiro Oki; Michinori Ogura; Harumi Kato; Ako Kikuchi; Hirofumi Taji; Yoshitoy 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 107 KB

Inducible lymphokine-activated killer (L

Inducible lymphokine-activated killer (LAK) cell activity in the peripheral blood of patients with relapsed/refractory non-Hodgkin's lymphoma (NHL)

✍ Kenneth W. Zamkoff; Nora P. Watman; David B. Duggan; Bernard J. Poiesz; Arlan J. 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 453 KB

Therapy with recombinant interleukin-2 (rIL-2) induces clinical response in a significant number of patients with refractory malignant disease. Very few patients with non-Hodgkin's lymphoma (NHL) have been treated with rIL-2. The present study sought to determine if peripheral blood mononuclear cell